Study design issues and early stage non-small cell lung cancer.

Joan H. Schiller

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The most common type of clinical trial in oncology enrolls patients with advanced disease. End points for phase II trials in advanced disease typically include response rate or time to progression, based upon the presumption that these may serve as surrogates for the ultimate end point of improved survival. Unique problems arise with the design of adjuvant trials, for which response rates clearly are not appropriate end points. In addition, survival is much longer, making rapid completion of phase III trials difficult. For lung cancer, the proportion of patients with stage I and II disease is much lower than with other types of cancer, and the absolute number of these patients is relatively low. To conduct large adjuvant trials in lung cancer more efficiently, we need to optimize our trials as much as possible. "Targeted therapies," by definition, inhibit a specific target, thus offering the theoretical advantage of enriching the patient population by restricting enrollment to patients whose tumor expresses the target of interest. Education of health care professionals regarding the benefits of adjuvant therapies, to decrease a sense of nihilism and to increase referrals, and international collaborations may also be necessary to increase accrual.

Original languageEnglish (US)
JournalClinical cancer research : an official journal of the American Association for Cancer Research
Volume11
Issue number13 Pt 2
StatePublished - Jul 1 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Survival
Neoplasms
Referral and Consultation
Biomarkers
Clinical Trials
Delivery of Health Care
Education
Therapeutics
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Study design issues and early stage non-small cell lung cancer. / Schiller, Joan H.

In: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 11, No. 13 Pt 2, 01.07.2005.

Research output: Contribution to journalArticle

@article{e4d6f3fac5f64d288b25d5ddc2ae0826,
title = "Study design issues and early stage non-small cell lung cancer.",
abstract = "The most common type of clinical trial in oncology enrolls patients with advanced disease. End points for phase II trials in advanced disease typically include response rate or time to progression, based upon the presumption that these may serve as surrogates for the ultimate end point of improved survival. Unique problems arise with the design of adjuvant trials, for which response rates clearly are not appropriate end points. In addition, survival is much longer, making rapid completion of phase III trials difficult. For lung cancer, the proportion of patients with stage I and II disease is much lower than with other types of cancer, and the absolute number of these patients is relatively low. To conduct large adjuvant trials in lung cancer more efficiently, we need to optimize our trials as much as possible. {"}Targeted therapies,{"} by definition, inhibit a specific target, thus offering the theoretical advantage of enriching the patient population by restricting enrollment to patients whose tumor expresses the target of interest. Education of health care professionals regarding the benefits of adjuvant therapies, to decrease a sense of nihilism and to increase referrals, and international collaborations may also be necessary to increase accrual.",
author = "Schiller, {Joan H.}",
year = "2005",
month = "7",
day = "1",
language = "English (US)",
volume = "11",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13 Pt 2",

}

TY - JOUR

T1 - Study design issues and early stage non-small cell lung cancer.

AU - Schiller, Joan H.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - The most common type of clinical trial in oncology enrolls patients with advanced disease. End points for phase II trials in advanced disease typically include response rate or time to progression, based upon the presumption that these may serve as surrogates for the ultimate end point of improved survival. Unique problems arise with the design of adjuvant trials, for which response rates clearly are not appropriate end points. In addition, survival is much longer, making rapid completion of phase III trials difficult. For lung cancer, the proportion of patients with stage I and II disease is much lower than with other types of cancer, and the absolute number of these patients is relatively low. To conduct large adjuvant trials in lung cancer more efficiently, we need to optimize our trials as much as possible. "Targeted therapies," by definition, inhibit a specific target, thus offering the theoretical advantage of enriching the patient population by restricting enrollment to patients whose tumor expresses the target of interest. Education of health care professionals regarding the benefits of adjuvant therapies, to decrease a sense of nihilism and to increase referrals, and international collaborations may also be necessary to increase accrual.

AB - The most common type of clinical trial in oncology enrolls patients with advanced disease. End points for phase II trials in advanced disease typically include response rate or time to progression, based upon the presumption that these may serve as surrogates for the ultimate end point of improved survival. Unique problems arise with the design of adjuvant trials, for which response rates clearly are not appropriate end points. In addition, survival is much longer, making rapid completion of phase III trials difficult. For lung cancer, the proportion of patients with stage I and II disease is much lower than with other types of cancer, and the absolute number of these patients is relatively low. To conduct large adjuvant trials in lung cancer more efficiently, we need to optimize our trials as much as possible. "Targeted therapies," by definition, inhibit a specific target, thus offering the theoretical advantage of enriching the patient population by restricting enrollment to patients whose tumor expresses the target of interest. Education of health care professionals regarding the benefits of adjuvant therapies, to decrease a sense of nihilism and to increase referrals, and international collaborations may also be necessary to increase accrual.

UR - http://www.scopus.com/inward/record.url?scp=24944562732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944562732&partnerID=8YFLogxK

M3 - Article

C2 - 16000609

AN - SCOPUS:24944562732

VL - 11

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13 Pt 2

ER -